The Latest Cardiac and Vascular News
BORDEAUX, France–(BUSINESS WIRE)–DESKi, a healthtech company developing AI-powered diagnostic tools in collaboration with clinicians and researchers, today announced the close of a $6 million seed round to support the U.S. and global market launch of its FDA-approved cardiac imaging software, HeartFocus. “This funding moves us one step closer to a world […]
Verve’s leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease Lilly’s established capabilities in cardiometabolic disease and genetic medicines are highly complementary to Verve’s vision and…
Existing investors provide funding to finish international RESPONDER-HF trial TEWKSBURY, Mass., June 17, 2025 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the successful closure of a $55 million funding round from…
FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that LockeT sales for Q2 2025 are on track to be the highest to date. Second quarter 2025 LockeT sales are already outpacing Q2 2024 sales with a 200% increase.
BARCELONA, Spain & MARIN, Calif.–(BUSINESS WIRE)–Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, announced today the appointment of long-time medtech executive Charles (Chuck) Carignan, M.D., as chairman of the board. Dr. Carignan is joining the company at a critical time as enrollment […]
DALLAS, June 10, 2025 /PRNewswire/ — Koya Medical (“Koya”), a global leader in vascular health innovation, today announced the grand opening of its new 35,000-square-foot headquarters in Dallas, Texas. This state-of-the-art facility becomes the new nerve center for Koya’s manufacturing…
The addition of the head of Sales Operations & Analytics aims to strengthen sales infrastructure and launch execution The addition of the head of Sales Operations & Analytics aims to strengthen sales infrastructure and launch execution
Founding CEO Tripp Higgins To Become Chairman of the Board of Directors, Supporting the Leadership Transition As Finkelmeier Puts Operational Structure in Place to Meet Growing Demand SARASOTA, Fla.–(BUSINESS WIRE)–PaceMate, the cardiac remote monitoring platform that leading healthcare providers trust, today announced the appointment of JR Finkelmeier as Chief Executive […]
HINGHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced that it has been selected for inclusion in the preliminary list of additions to the Russell Microcap® Index, as published by FTSE Russell on Friday, May 23, 2025. The newly reconstituted indexes are expected to take effect after U.S. market close on Friday, June 27, 2025, and be part of the 2025 Russell indexes reconstitution when the U.S. market opens on Monday, June 30, 2025.
KIRKLAND, Wash., June 05, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Conor Hanley as an independent director to its board, effective June 4, 2025. “I am delighted to welcome Conor to our board of directors,” said Brian Webster, President and CEO of Kestra Medical Technologies. “He brings deep expertise in medical technology and cardiac care and will serve as an invaluable strategic resource as we grow and expand the reach of the ASSURE® system.” Mr. Hanley is a chartered director and currently serves as CEO of FIRE1, a venture-backed connected medical device solutions company dedicated to improving outcomes for people with heart failure. He previously held senior management roles at ResMed, including leading the cardiology business unit and chronic disease management solutions globally. Prior to ResMed, Mr. Hanley was co-founder and CEO of BiancaMed, a medical device company that was acquired by ResMed. Mr. Hanley earned a PhD in chemical engineering from the University of Pennsylvania and an MBA from INSEAD. His previous board experience includes Enterprise Ireland and chair of APC Ltd. and the Irish MedTech association. “I am honored to join the Kestra board of directors,” said Mr. Hanley. “Kestra is driving much-needed innovation in the wearable cardioverter defibrillator market, and I look forward to collaborating with the management team as the company scales its operations and delivers on its commitments to patients and prescribers.” About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com. CONTACT: Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com
Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com
